Irinotecan
- Generic Name
- Irinotecan
- Brand Names
- Camptosar, Onivyde, Onivyde pegylated liposomal (previously known as Onivyde)
- Drug Type
- Small Molecule
- Chemical Formula
- C33H38N4O6
- CAS Number
- 97682-44-5
- Unique Ingredient Identifier
- 7673326042
- Background
Irinotecan is an antineoplastic enzyme inhibitor primarily used in the treatment of colorectal cancer. It is a derivative of camptothecin that inhibits the action of topoisomerase I. Irinotecan prevents religation of the DNA strand by binding to topoisomerase I-DNA complex, and causes double-strand DNA breakage and cell death. It is a derivative of camptothe...
- Indication
For the treatment of metastatic colorectal cancer (first-line therapy when administered with 5-fluorouracil and leucovorin). Also used in combination with cisplatin for the treatment of extensive small cell lung cancer. Irinotecan is currently under investigation for the treatment of metastatic or recurrent cervical cancer. Also used in combination with fluo...
- Associated Conditions
- Esophageal Cancer, Ewing's Sarcoma, Gastric Cancer, High Grade Glioma: Glioblastoma (GBM), Metastatic Cervical Cancer, Non-Small Cell Lung Cancer (NSCLC), Ovarian Cancer, Pancreatic Cancer, Rhabdomyosarcomas, Small Cell Lung Cancer (SCLC), Stage IV Colorectal Cancer, Recurrent, metastatic Colorectal carcinoma, Refractory, metastatic Pancreatic adenocarcinoma
- Associated Therapies
- -
Combination Chemotherapy in Treating Patients Who Have Advanced Solid Tumors
- Conditions
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2015-04-30
- Lead Sponsor
- National Cancer Institute (NCI)
- Registration Number
- NCT00020488
- Locations
- 🇺🇸
Warren Grant Magnuson Clinical Center - NCI Clinical Studies Support, Bethesda, Maryland, United States
Carboplatin and Irinotecan in Treating Children With Refractory Solid Tumors
- Conditions
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2013-04-05
- Lead Sponsor
- Bristol-Myers Squibb
- Registration Number
- NCT00024284
- Locations
- 🇺🇸
Memorial Sloan-Kettering Cancer Center, New York, New York, United States
🇺🇸Arizona Cancer Center, Tucson, Arizona, United States
🇺🇸Children's National Medical Center, Washington, District of Columbia, United States
Combination Chemotherapy in Treating Patients With Advanced Solid Tumors
- Conditions
- Interventions
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2014-02-24
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 13
- Registration Number
- NCT00046917
- Locations
- 🇺🇸
Memorial Sloan-Kettering Cancer Center, New York, New York, United States
Combination Chemotherapy Followed by Surgery in Treating Patients With Stage IIIA Non-small Cell Lung Cancer
- Conditions
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2013-07-25
- Lead Sponsor
- Yale University
- Target Recruit Count
- 10
- Registration Number
- NCT00003111
- Locations
- 🇺🇸
Yale Comprehensive Cancer Center, New Haven, Connecticut, United States
Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Locally Advanced Unresectable Pancreatic Cancer
- Conditions
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2021-09-09
- Lead Sponsor
- Wake Forest University Health Sciences
- Target Recruit Count
- 20
- Registration Number
- NCT00025168
- Locations
- 🇺🇸
East Carolina University School of Medicine, Greenville, North Carolina, United States
🇺🇸Spartanburg Regional Healthcare System, Spartanburg, South Carolina, United States
🇺🇸Southeastern Medical Oncology Center, Goldsboro, North Carolina, United States
Irinotecan Followed By Fluorouracil and Leucovorin in Treating Patients With Stage III or Stage IV Colorectal Carcinoma (Cancer), Other Refractory Carcinoma, or Metastatic Adenoma (Cancer) of Unknown Primary Origin
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2017-04-26
- Lead Sponsor
- St. Jude Children's Research Hospital
- Target Recruit Count
- 12
- Registration Number
- NCT00004005
- Locations
- 🇺🇸
St. Jude Children's Research Hospital, Memphis, Tennessee, United States
Combination Chemotherapy and Imatinib Mesylate in Treating Patients With Extensive-Stage Small Cell Lung Cancer
- Conditions
- Interventions
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2015-07-23
- Lead Sponsor
- University Health Network, Toronto
- Target Recruit Count
- 9
- Registration Number
- NCT00052494
- Locations
- 🇨🇦
Princess Margaret Hospital, Toronto, Ontario, Canada
Combination Chemotherapy in Treating Patients With Unresectable Metastatic Colorectal Cancer
- Conditions
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2013-12-19
- Lead Sponsor
- Medical Research Council
- Registration Number
- NCT00008060
- Locations
- 🇬🇧
Medical Research Council Clinical Trials Unit, London, England, United Kingdom
Combination Chemotherapy Followed by Surgery in Treating Patients With Stomach Cancer
- Conditions
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2011-04-06
- Lead Sponsor
- NYU Langone Health
- Registration Number
- NCT00004103
- Locations
- 🇺🇸
NYU Cancer Institute at New York University Medical Center, New York, New York, United States
Epirubicin Plus Irinotecan in Treating Patients With Advanced Cancer
- Conditions
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2011-03-24
- Lead Sponsor
- Georgetown University
- Registration Number
- NCT00020748
- Locations
- 🇺🇸
Lombardi Cancer Center at Georgetown University Medical Center, Washington, District of Columbia, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.